



June 3, 2021

Listing Department Code: 532 321

BSE LIMITED

P J Towers, Dalal Street, Fort,

<u>Mumbai – 400 001</u>

Listing Department Code: CADILAHC

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,

Bandra (E),

Mumbai - 400 051

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated June 3, 2021 titled "Zydus Cadila receives tentative approval from USFDA for Osimertinib Tablets".

The contents of the press release give full details.


Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully, For, **CADILA HEALTHCARE LIMITED**

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above



Zydus Cadila receives tentative approval from USFDA for Osimertinib Tablets

Ahmedabad, India, 3 June, 2021

Zydus Cadila has received tentative approval from the USFDA to market Osimertinib Tablets in the strengths of 40 mg and 80 mg (US RLD: Tagrisso Tablets). Osimertinib is used to treat lung cancer. It belongs to a class of drugs known as kinase inhibitors. Osimertinib works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 318 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

CIN: L24230GJ1995PLC025878